Microbiological and Pharmacological Evaluation of the Micropropagated Rubus liebmannii Medicinal Plant by Jiménez Arellanes, Adelina et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 503031, 7 pages
doi:10.1155/2012/503031
Research Article
Microbiological and Pharmacological Evaluation of
theMicropropagated Rubus liebmannii Medicinal Plant
Adelina Jime´nez-Arellanes,1 Jorge Cornejo-Garrido,1 Gabriela Rojas-Bribiesca,2
Marı´a del PilarNicasio-Torres,2 Salvador Said-Ferna´ndez,3, 4 BenitoDavidMata-Ca´rdenas,3, 4
Gloria Marı´a Molina-Salinas,3 Jaime Tortoriello,2 andMarianaMeckes-Fischer5
1Unidad de Investigacio´n Me´dica en Farmacolog´ıa, Hospital de Especialidades, CMNS XXI,
Instituto Mexicano del Seguro Social (IMSS), Avenue Cuauhte´moc 330, Col. Doctores, 06720 Mexico City, DF, Mexico
2Centro de Investigacio´n Biome´dica del Sur (CIBIS), IMSS, Argentina No. 1, 62790 Xochitepec, MOR, Mexico
3Centro de Investigacio´n Biome´dica del Noreste (CIBIN), IMSS, San Luis Potos´ı y Dos de Abril, Col. Independencia,
64720 Monterrey, NL, Mexico
4Facultad de Medicina, Universidad Auto´noma de Nuevo Leo´n (UANL), Avnue Fco. I. Madero y E. Aguirre Pequen˜o,
Col. Mitras Centro, Monterrey, NL, Mexico
5Centro de Diagno´stico en Metabolismo Energe´tico y Medicina Mitocondrial, Mexico City, DF, Mexico
Correspondence should be addressed to Adelina Jime´nez-Arellanes, adelinajim08@prodigy.net.mx
and Mariana Meckes-Fischer, meck7707@yahoo.com.mx
Received 20 April 2012; Accepted 14 June 2012
Academic Editor: Wagner Vilegas
Copyright © 2012 Adelina Jime´nez-Arellanes et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Rubus liebmannii is an endemic species from Mexico used in traditional medicine primarily to treat dysentery and cough. The
in vitro activity against Giardia lamblia and Entamoeba histolytica that produces the ethanolic extract of the aerial parts of the
plant led us to expand the pharmacological and phytochemical research of this species. Gastrointestinal disorders including
amebiasis remain one of the health problems that need to be addressed and it is of interest to find alternatives that improve
their treatment. Also, it is important to emphasize that R. liebmannii grows wild in the country and is not found in abundance;
therefore, alternatives that avoid overexploitation of the natural resource are mandatory. Ongoing with the evaluation of the
potentialities that R. liebmannii possesses for treating infectious gastrointestinal diseases, the aim of the present study was to
evaluate the biological eﬀects and the chemical composition of the micropropagated plant.
1. Introduction
Rubus genus (Rosaceae) comprises ca. 250 species distributed
worldwide. In Mexico, 28 species have been identified,
Rubus liebmannii Focke being an endemic species. The
plant, known as citun-zarza and tsituni in the Pure´pecha
language, as well as tunita del cerro, zarzamora, or zarza in
Spanish, grows wild in the State of Mexico and in those of
Michoaca´n and Jalisco [1, 2]. The ripe fruits are edible, and,
in traditional medicine, the infusion of the leaves is utilized
to treat diarrhea, cough, and insomnia. Ethnobotanical data
bases also report the employment of the infusion prepared
with the sprouts to treat dysentery [3]. A preliminary
study reported that the ethanolic extract from the aerial
parts of wild R. liebmannii possesses antiprotozoal activity
against Giardia lamblia and Entamoeba histolytica with 50%
Inhibitory concentration (IC50) = 56.12 and 51.43 μgmL−1,
respectively.The most active compounds isolated were (−)-
epicatechin and (+)-catechin, while β-sitosterol, squalene,
nigaichigoside F1, and 3,4-hydroxybenzoic acid were less
active against the tested protozoa [4]. Other species of Rubus
have exhibited antibacterial activity against Staphylococcus
aureus, S. epidermidis, Micrococcus luteus, Escherichia coli,
Bacillus subtilis, and Candida albicans [5–9].
In Mexico, gastrointestinal diseases are prominent as a
serious health problem, and intestinal amebiasis remains
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highly frequent [10]. As is well known, currently available
drugs for the treatment of these disorders may produce
severe side eﬀects and increase the appearance of multidrug-
resistant pathogens. G. lamblia and E. histolytica are two
of the most clinically important anaerobic protozoa that
cause diarrheal disease worldwide. Recently, giardiasis was
included in the “Neglected Disease Initiative,” estimating that
280 million people are infected each year with G. lamblia
[11].
On the other hand, tuberculosis aﬀected about one
third of the world’s population, and its treatment remains
a challenge that requires new antitubercular agents due
to the emergence of multidrug-resistant and extensively
resistant Mycobacterium tuberculosis strains. In addition,
antimicrobial-resistant bacteria are the causes of numerous
clinical problems worldwide. The increase of resistance
among pathogens causing nosocomial and community-
acquired infections are known to be associated with
widespread and overutilization of antibiotics. Infectious
diseases caused by resistant microorganism are responsible
for increased health costs as well as for high morbidity
and mortality, particularly in developing countries. Many
bacterial strains are resistant to the actual antibiotics and
have increased cost in terms of treatment; for example,
Enterococcus faecalis, Pseudomona aeruginosa, and others
are resistant to tetracyclines, aminoglycosides, and fluoro-
quinolones [12, 13]. This situation led to the search for
novel alternatives, and medicinal plants represent a natural
source that requires exploration. Furthermore, the applica-
tion of biotechnological processes permits harvesting, from
micropropagation-generated plants, high raw vegetal mate-
rial with constant characteristics without producing ecosys-
tem alteration; some protocols were previously designed to
obtain high regeneration rates of many plant species in
vitro [14, 15]. The aim of the present study was to evaluate
the pharmacological potential of the micropropagated R.
liebmannii plant.
2. Methods
2.1. Plant Material. R. liebmannii plant material for this
study was obtained from the Acotzingo Greenhouse in the
State ofMexico. The species was identified by Abigail Aguilar,
M.Sc., and a voucher specimen (15287) was deposited at the
IMSSM Herbarium.
2.2. Micropropagation. The micropropagation protocol was
carried out in the South Biomedical Research Center (CIBIS)
of the Mexican Institute of Social Security (IMSS). R. lieb-
mannii micropropagated plants were obtained from axillary
bud explants excised and inoculated in Murashige and Skoog
medium supplemented with 30 gL−1 sucrose, 8 gL−1 agar,
6-Benzylaminopurine (BAP, 3.32 μM), and Indole-3-acetic
acid (IAA, 0.57 μM). Multiple shoots were obtained from
a singular bud during a 60-day culture period. In vitro
grown shoots were successfully rooted and acclimatized
to greenhouse conditions. Conditions for the plants were
gradually changed until an adequate environment for growth
directly in the soil was reached (90% survival).
2.3. Extract Preparation. The dried powdered aerial parts of
the micropropagated plant (1,500 g) were macerated with
ethanol (3 × 12 L) at room temperature for 72 h. After
filtration, the extract was concentrated to dryness under
low pressure at 40◦C to obtain 250 g of the crude extract
(16.7%w/w).
2.4. Chemical Study. The ethanolic extract (50 g) was frac-
tionated by column chromatography on Si gel (Merck) to
obtain 15 primary fractions. All fractions were submitted
to antimicrobial and spasmolytic testing. Stigmastan-3,5-
diene and β-sitosterol were detected in F9 as the major
compounds, and F10–F12 rechromatographed on Si gel led
to the isolation of 12 secondary fractions (FA–FL), while the
combined fraction (FD–FE) rendered 45mg (−) epicatechin
and 34mg nigaichigoside F1 after preparative thin-layer
chromatography (TLC) using CHCl3-Et2O (9 : 1) as mobile
phase. Chemical identification of these compounds was
performed by comparison of spectroscopic data with those
of authentic samples.
2.5. Test Organisms. Microorganisms comprised Staphylo-
coccus pyogenes (ATCC 29213), Enterococcus faecalis (ATCC
29212), Escherichia coli (ATCC 25922), Proteus mirabilis
(ATCC 43071), Salmonella typhi (ATCC 06539), Mycobac-
terium tuberculosis H37Rv (ATCC 27294), Candida albicans
(ATCC 10231), Trichophyton mentagrophytes (ATCC 28185),
and T. rubrum (ATCC 28188). Bacteria were maintained
and tested on Trypticase soy agar (TSA, Merck) at 37◦C,
and yeast and fungi, on Sabouraud 4% dextrose agar (SDA,
Merck). M. tuberculosis H37Rv was cultured in Middlebrook
7H9 broth supplemented with 0.2% glycerol and 10%OADC
(Oleic acid-Albumin-Dextrose, and Catalase) enrichment.
Entamoeba histolytica (HMI-IMSS) and Trichomonas vagi-
nalis (GT-13) were grown under axenic conditions in PEHPS
medium [16]. Giardia lamblia (0989:IMSS) was cultivated in
TYI-S-33 medium as modified by Keister [17].
2.6. Antiprotozoan Assay. The method to determine the anti-
protozoan activity of our preparations was performed as
described elsewhere [16, 18]. All protozoa species were incu-
bated at 37◦C and subcultivated twice weekly. When each
protozoa culture was grown logarithmically, trophozoites
were harvested and suspended in 50 μL phosphate-buﬀered
saline, pH 7.4 (PBS) at the following concentrations: E.
histolytica 20 × 103; G. lamblia 20 × 104 cell, and T. vaginalis
10 × 104 trophozoites per mL−1. These suspensions were
inoculated separately in 1mL screw-capped borosilicate vials
(Bellco, Vineland, NJ, USA) containing 1 mL of PEHPS for
E. histolytica and T. vaginalis, or TYI-S-33 for G. lamblia.
E. histolytica cultures were incubated at 37◦C for 72 h, and
those of T. vaginalis and G. lamblia, for 24 h. Vials were
added containing 50 μL of various concentrations of the R.
liebmannii extract of interest (10–0.31 μg mL−1). The extract
was serially diluted with 100% DMSO in twofold steps. A
control containing 50 μL of DMSO was included in each
assay. After 48 h of incubation at 37◦C, the trophozoites were
harvested, washed twice with PBS, and reincubated for 48 h
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in the corresponding fresh medium. The trophozoites from
each vial were counted with a hemacytometer. In each assay,
metronidazole and emetine were included as internal con-
trols. Concentrations of these drugs were as follows: emetine
(0.7 μgmL−1) was used exclusively in the E. histolytica assays,
and metronidazole at 1.6, 1.0, and 0.5 μgmL−1 was used for
E. histolytica, T. vaginalis, and G. lamblia, respectively. The
inhibitory eﬀect of the R. liebmannii extract was estimated
as the decreased percentage of trophozoite number with
respect to nontreated cultures. Corresponding averages and
standard deviations (SD) were plotted. The fifty percent
inhibitory concentration (IC50) of the R. liebmannii extract
was expressed as the concentration that produced a 50%
decrease of trophozoite concentration in each of the three
protozoa species. Each determination was performed three
times, in triplicate. The eﬀect of metronidazole or emetine
was expressed as a diminution percentage with respect to
nontreated controls.
2.7. Antibacterial Assay. The extract dissolved in DMSO
(Merck) was added to the agar culture medium at con-
centrations of 1, 2, 4, and 8mgmL−1. Inocula containing
107 colony-forming units (CFU)mL−1 for bacteria and 106
CFUmL−1 for yeast were applied with a steer replicator,
and samples were incubated for 24 h at 37◦C. Gentamycin
(for bacteria), nystatin (for yeast), and ketoconazole (for
fungi) were included as reference standards, and assays
were performed by duplicate and repeated twice. Results
were expressed as the lowest concentration of the extract
that produced complete suppression of the colony growth
(minimal inhibitory concentration (MIC)) [19].
The previously described Microdilution alamar blue
assay (MABA) was utilized to determine the antimycobac-
terial eﬀect of the plant extract [20] prepared at an initial
concentration of 4mgmL−1 in DMSO (Sigma-Aldrich)
and was further diluted in Middlebrook 7H9 broth. The
concentration of the EtOH extract and pure compounds
tested ranged from 100 to 3.13 μgmL−1. Rifampin (Sigma-
Aldrich) was used as positive control with concentrations
ranging from 2.00 to 0.06 μgmL−1.
2.8. Relaxant Eﬀect on In Vitro Guinea-Pig Ileum. The
relaxant eﬀect of the samples (extract, fractions, and pure
compounds) was evaluated in the spontaneous contractile
response induced by K+ in isolated guinea-pig ileum fol-
lowing the methodology described by Meckes [21]. Male
guinea pigs weighing 450–600 g were stunned and bled.
The distal ileum (10 cm above the ileocecal junction) was
removed and placed in a Tyrode solution of milliMolar
(mM) composition: NaCl, 136; KCI, 2.68; CaCl2, 1.84;
MgCl2, 0.49; NaH2PO4, 0.36; NaHCO3, 11.10; glucose, 11.10
(pH 7.4). Segments of ileum (1.5 cm) oriented along their
longitudinal axis sections were suspended in 10 mL organ
baths containing Tyrode solution at 37◦C, bubbled with
95% O2/5% CO2, and at a resting tension of 1 g. After a
60min equilibration period, isometric contractions induced
by high-K+ (60mM) depolarizing Tyrode were recorded
through a Grass force-displacement transducer (FTO3C)
connected to the Grass-7D polygraph. The composition of
Tyrode depolarizing solution was (in mM) as follows: NaCl,
78.68; KCI, 60.00; CaCl2, 1.84; MgCl2, 0.49; NaH2PO4, 0.36;
NaHCO3, 11.10; glucose, 11.10 (pH 7.4).
2.9. Toxicological Assay. The study with animals was per-
formed according to the guidelines of the local Ethics Com-
mittee for Experimentation in Animals in Mexico (Ministry
of Agriculture, NOM-062-ZOO-1999, Mexico) modified in
2001 and was approved by the Institutional Animal Care and
Use Committee. Animals were maintained under standard
environmental conditions at 12 h light/dark photoperiods.
All animals were supplied with food and water ad libitum
during the testing period.
Acute toxicity was determined in male and female
Balb/c (weight, 22 ± 2.2 g) mice and Sprague-Dawley rats
(weight, 220± 22.0 g) following the methodology previously
described by Lorke [22]. The rodents were randomly divided
per gender into five groups of three animals each. Group 1
was the control DMSO :H2O (3 : 7), and groups 2–5 were
treated orally with the extract at 1, 1.6, 2.9, and 5 g kg−1. The
extract solubilized in DMSO :H2O (3 : 7) was administered
intragastrically in a volume of not >10mL kg−1, and the
general behavior of the treated animals was observed at 1,
2, 4, 6, and 24 h, and daily for 14 days. At the end of the
study, the internal organs (lung, kidney, heart, spleen, and
liver) were extracted, and a gross pathological observation
was performed. The 50% Lethal dose (LD50) value was
determined by Probit.
Subacute toxicity was determined following the method-
ology previously described by OECD TG407 [23]. Twenty-
five male Sprague-Dawley rats (weight, 220 ± 22.0 g) were
randomly assigned to five groups with five animals per group.
The crude extract was administered orally by gavage once
daily for 21 days. Groups 1 and 2 received distilled water or
the vehicle DMSO :H2O (3 : 7), and groups 3–5 were treated
with the extract at daily doses of 10, 100, and 1,000mg kg−1.
General behavior was observed daily, and the weight of the
animals was registered once a week. Animals that died during
the test period were analyzed pathologically, and those that
survived were examined at the end of the experimentation
phase.
On day 21, the rats were fasted overnight and anes-
thetized with sodium pentobarbital (56mg kg−1) for blood
collection from right ventricle. Heparinized blood samples
were taken for determining complete blood count (CBC), red
blood cell count (RBC), hemoglobin concentration (HGB),
hematocrit (HCT), mean corpuscular volume (MCV), mean
corpuscular hemoglobin concentration (MCHC), platelets,
white blood cell count (WBC), neutrophils, lymphocytes,
monocytes, eosinophils, and basophils. Serum from non-
heparinized blood was carefully collected for blood chem-
istry, and enzyme analyses were conducted to determine
glucose (GLU), UREA, creatinine (CREAT), total choles-
terol (CHOL), triglycerides (TRI), high-density cholesterol
(HDL), low-density cholesterol (LDL), aspartate amino
transferase (AST), alanine amino transferase (ALT), alkaline
phosphatase (ALP), gamma glutamyl transferase (γGT),
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uric acid (UrAc), total bilirubin (TB), and conjugated
bilirubin (DIRB). Hematological and chemistry analyses
were performed employing automated equipment (Coulter
T890 and Selectra II, resp.).
Immediately after blood collection, all animals were
sacrificed, internal organs (liver, intestine, spleen, and
kidney) were removed and weighed to determine relative
organ weight, and gross alterations were observed. The
tissues were preserved in 10% formaldehyde solution for
histological examination, and tissues of the groups treated
with the highest dose of the extract (1.0 g kg−1 day−1) and
their corresponding controls were embedded in paraﬃn
and subjected to hematoxylin-eosin staining. The organs
of animals treated with lower doses were histologically
examined only when lesions were detected at highest doses.
2.10. Statistical Analysis. Results are expressed as mean ±
standard error of mean (SEM). Significance diﬀerences
between controls and experimental groups were assessed by
Student t test, considering P < 0.05 as significant.
3. Results and Discussion
In Mexico, the culture of medicinal plants is a scarce
phenomenon, and the current demand for these species has
increased notably, a circumstance that forces us to search for
options to protect these plants from overcollection. Micro-
propagation technology from existing meristems allows for
continuous production of plants that are genetically identical
to wild plants [14]. The present paper describes the biological
and chemical properties of micropropagated R. liebmannii,
correlating the eﬀects with those of the wild species. As
a first step, the ethanolic extract from the aerial parts
of the micropropagated plant was submitted to biological
testing to evaluate antiprotozoan activity (Table 1). The
results obtained demonstrated a significant eﬀect against
G. lamblia (IC50 = 11.75 μgmL−1), that is, more potent
than the eﬀect previously reported for the same extract
obtained from the aerial parts of the wild plant (IC50 =
56.12 μgmL−1) [4]. The growth of E. histolyticawas inhibited
with a notably lower potency (IC50 > 100 μgmL−1) than the
reported eﬀect of the wild plant (IC50 = 51.43 μgmL−1). By
comparing these preliminary results, it is possible to assume
that although the micropropagated plant material possesses
antiprotozoan properties, biological diﬀerences with the wild
plant could be found. It is well known that many factors exert
an important influence on the biosynthesis of secondary
metabolites, such as seasonal collection and environmental
and ecological factors (temperature, humidity, altitude, soil,
and soil microflora) of areas where the plants grow [14, 15].
Chemical fractionation of the ethanolic extract from the
micropropagated plant led to obtaining the polyphenol (−)-
epicatechin and the triterpenoid nigaichigoside F1 isolated
previously from the wild plant [4]; however, (+)-catechin
was not detected in the micropropagated plant extract,
probably a factor that could explain, in part, the diﬀerence
between the species’ biological eﬀect. The isolated (−)-
epicatechin showed an IC50 = 30.2 μgmL−1 against E.
Table 1: Antiprotozoal activity of ethanol extract and pure
compounds from micropropagated Rubus liebmannii.
Sample
IC50 (μgmL−1)
E. histolytica G. lamblia T. vaginalis
Ethanolic extract >100 11.75 >100
(−)-Epicatechin 30.2 31.5 31.5
Nigaichigoside F1 20.5 2.17 4.92
Metronidazole 1.6 0.5 1.0
IC50: 50% Inhibitory concentration; E. histolytica: Entamoeba histolytica;
G. lamblia: Giardia lamblia; T. vaginalis: Trichomonas vaginalis.
Table 2: Relaxant eﬀect induced by ethanol extract and primary
fractions from Rubus liebmannii on spontaneous concentration of
ileum.
Sample IC50 (μgmL−1)
Ethanolic extract >250
F6 NT
F7 52.99 ± 4.74
F8 27.66 ± 3.41
F9 6.22 ± 0.73
F10 14.87 ± 0.33
F11 >250
F12 34.74 ± 6.81
F13 61.71 ± 9.8
F14 >250
F15 57.50 ± 5.76
β-sitosterol 42.81 ± 3.42
(−)-Epicatechin∗ >200
Papaverine 14.1 ± 0.35
IC50: 50% Inhibitory concentration; NT: Not tested. ∗Sigma.
histolytica and an IC50 = 31.5 μgmL−1 against G. lamblia
and T. vaginalis. Nigaichigoside F1 with IC50 = 20.5 μgmL−1
against E. histolytica was highly potent against G. lamblia
(IC50 = 2.17 μgmL−1) and against T. vaginalis (IC50 =
4.92 μgmL−1). The antigiardial activity of (−)-epicatechin
was also evaluated in vivo, resulting in a 50% eﬀective dose
(ED50) = 0.072 μmol kg−1 in suckling female CD-1 mice
[24, 25].
Taking into account that R. liebmannii is used to
treat infectious diseases (gastrointestinal and respiratory
ailments) and that the antibacterial and antifungal eﬀects
of R. ulmifolius, R. cordifolius, and R. chamaemorus have
been described [5, 7, 8], the crude extract and some of the
primary and secondary fractions of the micropropagated
R. liebmannii were tested for antibacterial, antifungal, and
antimycobacterial activities. The extract was active only
against S. aureus (MIC = 1mgmL−1), and moderate activity
was also detected against T. rubrum and T. mentagrophytes
dermatophytes (MIC = 2mgmL−1); nevertheless, pure iso-
lated (−) epicatechin and nigaichigoside F1 were inactive
against all microorganisms tested (MIC > 8mgmL−1)
(data not shown). The crude extract showed a significative
eﬀect against M. tuberculosis H37Rv (MIC = 0.1mgmL−1)
although the pure compounds isolated [(−) epicatechin and
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Table 3: Hematological values and white blood cell count of male rats in subacute toxicity of the ethanol extract from Rubus liebmannii.
Male rats Vehicle control
Doses (mg kg−1)
10 100 1,000
RBC × 106 μL−1 7.67 ± 0.32 7.67 ± 0.07 8.068 ± 0.07 7.67 ± 0.27
HGB g dL−1 14.9 ± 0.65 15.64 ± 0.14 15.98 ± 0.15 15.3 ± 0.26
HCT (%) 43.38 ± 1.20 45.66 ± 0.29 46.36 ± 0.43 44.36 ± 1.10
MCV (fl) 56.5 ± 0.61 59.46 ± 0.25 57.48 ± 0.41 57.86 ± 0.70
MCHC g dL−1 34.34 ± 0.22 34.28 ± 0.29 34.48 ± 0.29 34.48 ± 0.37
Platelet (×108 μL−1) 7.974 ± 0.78 9.78 ± 0.46 10.56 ± 0.86 10.57 ± 0.67
WBC (×103 μL−1) 7.44 ± 1.10 7.2 ± 0.70 10.3 ± 1.48 8.04 ± 2.11
Lymphocyte (%) 81.2 ± 3.13 81.6 ± 1.88 62.8 ± 9.54 71.6 ± 2.50
Neutrophil (%) 18.4 ± 3.32 17.8 ± 2.26 37 ± 9.59 27.8 ± 2.26
Eosinophil (%) 0.8 ± 0.58 0.2 ± 0.2 0.2 ± 0.2 0.4 ± 0.24
Monocyte (%) 0 ± 0 0.4 ± 0.24 0 ± 0 0.2 ± 0.2
Basophil (%) 0 ± 0 0 ± 0 0 ± 0 0 ± 0
RBC: Red blood count; HGB: Hemoglobin; HCT: Hematocrit; MCV:Mean corpuscular volume; MCHC:Mean corpuscular hemoglobin concentration;WBC:
White blood count. Results are means ± Standard error of the mean (SEM); n = 5; P < 0.005.
Table 4: Blood chemistry values of male rats in subacute toxicity of the ethanol extract from aerial parts of Rubus liebmannii.
Male rats Vehicle control
Doses (mg kg−1)
10 100 1000
GLU mgdL−1 185.55 ± 11.03 178.42 ± 13.60 175.69 ± 7.39 189.81 ± 20.92
UREA mgdL−1 50 ± 3.03 53.40 ± 1.63 51.26 ± 3.61 61.80 ± 1.34
UrAc mg dL−1 2.42 ± 0.37 2.15 ± 0.29 1.26 ± 0.18 1.98 ± 0.18
CHOL mmol L−1 22.78 ± 1.39 22.14 ± 1.28 21.74 ± 1.61 22.39 ± 1.42
TRI mmol L−1 0.72 ± 0.05 0.89 ± 0.14 0.61 ± 0.04 0.78 ± 0.17
HDL mmol L−1 5.55 ± 0.17 5.82 ± 0.35 4.36 ± 0.72 5.20 ± 0.17
LDL mmol L−1 1.72 ± 0.10 1.73 ± 0.1 1.85 ± 0.30 1.66 ± 0.10
CREAT mg dL−1 0.53 ± 0.04 0.58 ± 0.03 0.38 ± 0.06 0.67 ± 0.02
TB mg dL−1 0.33 ± 0.03 0.25 ± 0.01 0.25 ± 0.01 0.29 ± 0.03
DIRB mg dL−1 0.45 ± 0.08 0.27 ± 0.06 0.22 ± 0.02 0.41 ± 0.10
ALP U L−1 605 ± 4.42 602.4 ± 59.27 483.4 ± 52.50 562.4 ± 40.91
AST U L−1 105.19 ± 8.12 79.88 ± 2.63 84.28 ± 25.81 163.71 ± 18.10
ALT U L−1 63.28 ± 3.35 67.92 ± 3.87 43.59 ± 6.97 82.12 ± 2.13
γGT U L−1 0.74 ± 0.05 0.78 ± 0.08 0.52 ± 0.13 0.79 ±0.06
GLU: Glucose; UrAc: Uric acid; CHOL: Total cholesterol; TRI: Triglycerides; HDL: High-density cholesterol; LDL: Low-density cholesterol; CREAT: Creatinine;
TB: Total bilirubin; DIRB: Direct bilirubin; ALP: Alkaline phosphatase; γGT: gamma Glutamyl transferase; AST: Aspartate amino transferase; ALT: Alanine
amino transferase. Results are means ± Standard error of the mean (SEM); n = 5; P < 0.005.
nigaichigoside F1] were inactive against this strain (MIC > 0.
1mgmL−1).
Contractions induced with high K+-depolarizing Tyrode
reached a steady level of tension after 40–50min (Emax =
100%). Further addition of cumulative concentrations of the
plant products produced concentration-dependent inhibi-
tion of the sustained tonic contractile response. The potency
of the inhibitory eﬀect (IC50), calculated by the nonlinear
fitting curve, showed F8–F10 to be the most active fractions
(6.22–27.66 μgmL−1), being F9 as potent as papaverine (6.70
± 1.31 μM), the well-known antispasmodic agent that was
included in this assay as a reference (Table 2). The main
compounds in these fractions include stigmastan-3,5-diene
and β-sitosterol. Although (−) epicatechin was detected in
fractions F10–F12, the pure compound was not eﬀective as
an antispasmodic agent (IC50 > 200 μgmL−1).
The ethanol extract submitted to toxicological evaluation
showed it to be a nontoxic product. LD50 obtained by Lorke
procedure was >5 g kg−1 when both rodents’ species were
administered with the extract intragastrically. No death was
registered throughout the 14 days of observation, nor did we
observe macroscopic physical alteration in liver, kidney, lung,
or body weight.
On the other hand, after administration of repeated doses
of the extract (10, 100, and 1,000mg kg−1) for 21 consecutive
days, no adverse eﬀects or deaths were detected in the treated
groups. Body weights increased in constant fashion in all
groups, and nonsignificant variation was observed when
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Figure 1: Photomicrographs of liver, kidney, spleen, and intestine
from male Sprague-Dawley rats in subacute toxicity of the extract
from aerial parts of Rubus liebmannii. Cross-sections were stained
with hematoxylin and eosin at ×400 (for liver and kidney) and at
×100 (for spleen and intestine). Observations were conducted at
diﬀerent amplified levels. The liver cross-section shows the hepatic
artery (HA), bile duct (BD), central vein (CV), sinusoids (S),
and hepatocytes (H), all clearly conserved. Cross-section of kidney
shows, on magnification, renal corpuscles (RC), tubules (T), and
Bowman’s space (BS), all sealed. Spleen cross-section shows red
pulp (RP) and white pulp (WP) containing central arteries (CAs),
all well defined. Cross-section of intestine shows Peyer patches (PPs)
and intestinal mucosa (IM), with all of these structures also found
to be totally conserved.
comparing these with those of the controls; similarly, organ
weight of the treated animals was not aﬀected by the extract
(data not shown). Hematological analysis did not show
variations when compared to that of the control (Table 3).
In clinical blood chemistry analyses, we observed that oral
administration of the extract produced no alterations in any
determined parameter (Table 4). Regarding hepatic and renal
functions, the values of the serum transaminases ALP, AST,
and ALT were normal, which permits us to assume that the
extract does not produce a hepatic toxic eﬀect; on the other
hand, UREA and CREAT also demonstrated normal levels in
comparison with the respective controls.
At the end of treatment with the extract, histological
examination of liver, kidney, spleen, and intestine showed
normal architecture, suggesting no morphological distur-
bances (Figure 1). Renal cortex and renal corpuscles were
preserved, as well as tubule types (see Figure 1, kidney).
4. Conclusion
Themicropropagated Rubus liebmannii species is a non-toxic
plant with antiprotozoal and antispasmodic properties that
may have potential as a therapeutic product. The in vitro
culture method that has been developed to propagate the
species allows the proposal of a clinical trial to demonstrate
the safety and eﬃcacy of this plant for treating amebiasis and
giardiasis, two gastrointestinal parasitic infections with high
prevalence in the majority of developing countries.
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